Xeris Pharmaceuticals Announces Pricing of Public Offerings of $20 Million of Common Stock and $75 Million of 5.00% Convertible Senior Notes Due 2025
Stock Information for Xeris Biopharma Holdings Inc.
Loading
Please wait while we load your information from QuoteMedia.